The benzodiazepine binding site of GABAA receptors as a target for the development of novel anxiolytics

@article{Atack2005TheBB,
  title={The benzodiazepine binding site of GABAA receptors as a target for the development of novel anxiolytics},
  author={J. Atack},
  journal={Expert Opinion on Investigational Drugs},
  year={2005},
  volume={14},
  pages={601 - 618}
}
  • J. Atack
  • Published 2005
  • Chemistry, Medicine
  • Expert Opinion on Investigational Drugs
Non-selective benzodiazepine (BZ) binding-site full agonists, exemplified by diazepam, act by enhancing the inhibitory effects of GABA at GABAA receptors containing either an α1, -2, -3 or -5 subunit. However, despite their proven clinical anxiolytic efficacy, such compounds possess a relatively narrow window between doses that produce anxiolysis and those that cause sedation, and are also associated with physical dependence and a potential for abuse. In the late 1980s and early 1990s a number… Expand
Chapter 4.2 Subtype-selective GABAA/benzodiazepine receptor ligands for the treatment of anxiety disorders
Anxiety disorders can be treated successfully with benzodiazepines, which act by binding to a site on the γ-aminobutyric acid type A (GABAA) receptor and potentiating the inhibitory effects of GABA.Expand
Flavan-3-ol derivatives are positive modulators of GABAA receptors with higher efficacy for the α2 subtype and anxiolytic action in mice
TLDR
The compound Fa131 demonstrated improved segregation of anxiolytic and sedative doses when compared to the non-selective agonist diazepam, and flavan derivatives highlight the potential of targeting non-benzodiazepine allosteric sites in the search for new anxioselective drugs. Expand
Development of subtype-selective GABAA receptor compounds for the treatment of anxiety, sleep disorders and epilepsy
There is little doubt regarding the therapeutic possibilities of modulation of GABAA receptor function as exemplified by the clinical utility of benzodiazepines for half a century. The emergingExpand
GABAA Receptor α2/α3 Subtype-Selective Modulators as Potential Nonsedating Anxiolytics
TLDR
Data indicate that the pharmacological profile of compounds that differentially modulate specific populations of GABAA receptors is distinct from classical benzodiazepines and should encourage further preclinical and clinical investigation of such compounds, with the caveat that, as exemplified by MRK-409, the preclinical profile might not necessarily translate into man. Expand
Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABAA α2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers
TLDR
Although less effect on VAs alertness was expected, diminished effects on memory and postural stability were present and clinical studies in anxiety patients should show whether this dose of MK-0343 is therapeutically effective with a different side-effect profile. Expand
GABAA Receptor Physiology and Its Relationship to the Mechanism of Action of the 1,5-Benzodiazepine Clobazam
TLDR
Clobazam was synthesized with the anticipation that its distinct chemical structure would provide greater efficacy with fewer benzodiazepine-associated adverse effects, and evidence gathered from approximately 50 epilepsy clinical trials indicated that the sedative effects observed with clobzam treatment were less severe than those reported with 1,4-benzodiazepines. Expand
Development and SAR of functionally selective allosteric modulators of GABAA receptors.
TLDR
The functional SAR of cinnolines and quinolines that are positive allosteric modulators of the α2- and α3-containing GABA(A) receptors, while simultaneously neutral antagonists at α1-containing glutamate receptors, is described. Expand
The specificity of different selective and non-selective gabaa (partial) agonists in healthy volunteers
Different selective gabaa -ligands are in development to treat anxiety and sleep disorders. The Central Nervous System (cns) effects of various selective and non-selective (partial) gabaa agonistsExpand
The specificity of different selective and non-selective gabaa (partial) agonists in healthy volunteers
Different selective gabaa -ligands are in development to treat anxiety and sleep disorders. The Central Nervous System (cns) effects of various selective and non-selective (partial) gabaa agonistsExpand
A Review of the Updated Pharmacophore for the Alpha 5 GABA(A) Benzodiazepine Receptor Model
TLDR
An updated model of the pharmacophore for α5β2γ2 Bz/GABA(A) receptors, including a rendering of PWZ-029 docked within the α5-binding pocket showing specific interactions of the molecule with the receptor. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 150 REFERENCES
Anxioselective compounds acting at the GABA(A) receptor benzodiazepine binding site.
  • J. Atack
  • Chemistry, Medicine
  • Current drug targets. CNS and neurological disorders
  • 2003
TLDR
Efficacy selective compounds are developed which retain the anxiolytic properties of the full agonist BZs but have reduced sedation and dependence (withdrawal) liabilities and represent a novel approach to targeting specific subtypes of the GABA(A) receptor. Expand
Novel anxiolytics that act as partial agonists at benzodiazepine receptors.
TLDR
Partial agonists for the benzodiazepine modulatory site on the GABAA complex have been developed and their pharmacological profiles can be interpreted to suggest that neurons mediating anticonvulsant and anti-anxiety effects do indeed have a higher receptor reserve than neuronsmediating other unwanted effects. Expand
Benzodiazepine recognition site ligands and GABAA receptors
The benzodiazepine recognition site of the mammalian brain GABAA receptor (responsible for the majority of neuronal inhibition in the mammalian CNS) has taken its name from the chemical structuresExpand
Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABAA receptor α1 subtype
TLDR
This work created genetically modified mice with a diazepam-insensitive α1 subtype and a selective BZ site ligand to explore GABAA receptor subtypes mediating specific physiological effects and revealed that the α1Subtype mediated the sedative, but not the anxiolytic effects of benzodiazepines. Expand
α-Subunit selective modulators of GABAA receptor function as CNS therapeutics
TLDR
This article focuses on new ligands that are reported to selectively recognise particular α-subunits of GABAA receptors and may thereby offer improved treatments for CNS disorders. Expand
Selective antagonists of benzodiazepines
TLDR
The main properties of a representative of this novel class of specific benzodiazepine antagonists are described, whose unique pharmacological activity is to prevent or abolish in a highly selective manner at the receptor level all the characteristic centrally mediated effects of active Benzodiazepines. Expand
Benzodiazepine actions mediated by specific γ-aminobutyric acidA receptor subtypes
GABAA (γ-aminobutyric acidA) receptors are molecular substrates for the regulation of vigilance, anxiety, muscle tension, epileptogenic activity and memory functions, which is evident from theExpand
Imidazenil: a new partial positive allosteric modulator of gamma-aminobutyric acid (GABA) action at GABAA receptors.
TLDR
Imidazenil, an imidazobenzodiazepine carboxamide, has been characterized as a novel representative of the partial allosteric modulator class and possesses a marked anticonflict profile in the rat Vogel conflict-punishment test. Expand
Benzodiazepines on trial: a research strategy for their rehabilitation.
TLDR
Partial allosteric modulators, such as imidazenil, which have high potency and low intrinsic activity at GABA-gated Cl- channels are discussed, which are an example of a new type of anxiolytic and anticonvulsant drug acting at GABAA receptors via benzodiazepine recognition sites. Expand
Different GABAA receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primates.
TLDR
The results provide evidence in nonhuman primates that alpha1GABAA receptors do not play a key role in the anxiolytic and muscle-relaxant properties of benzodiazepine-type drugs; instead, these effects involve alpha2GabAA, alpha3GABaa, and/or alpha5GAB AA subtypes. Expand
...
1
2
3
4
5
...